Circulating levels of ghrelin or proghrelin-derived peptides are altered in cardiovascular diseases such as cardiac ischemia, type 2 diabetes mellitus and obesity [42], [43], [44]. Here, GHRL is linked to obesity due to melanocortin 4 receptor deficiency.